FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2023/12/060758 [Registered on: 26/12/2023] Trial Registered Prospectively
Last Modified On: 21/07/2025
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Yoga & Naturopathy 
Study Design  Randomized, Parallel Group Trial 
Public Title of Study   Effect of Yoga on heart and vascular health in heart failure patients 
Scientific Title of Study   Yoga-based Cardiac Rehabilitation: Exploring its Mechanism on Heart Failure through Assessing Endothelial Function, Gene Expression, and Arterial Health (Yog-EndOmics)  
Trial Acronym  Yog-EndOmics 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Vindya Vasu Shetty 
Designation  Senior Research Fellow 
Affiliation  SDM College of Medical Sciences and Hospital 
Address  Laboratory for Advanced Research in Yoga and Vascular Physiology, Department of Physiology, SDM College of Medical Sciences and Hospital, Manjushree Nagar, Sattur, Dharwad

Dharwad
KARNATAKA
580009
India 
Phone  9535603717  
Fax    
Email  drvindyashetty@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Satish G Patil 
Designation  Associate Professor 
Affiliation  SDM College of Medical Sciences and Hospital 
Address  Laboratory for Advanced Research in Yoga and Vascular Physiology, Department of Physiology, SDM College of Medical Sciences and Hospital, Manjushree Nagar, Sattur, Dharwad

Dharwad
KARNATAKA
580009
India 
Phone  9986789583  
Fax    
Email  satish.patil@sdmuniversity.edu.in  
 
Details of Contact Person
Public Query
 
Name  Dr Satish G Patil 
Designation  Associate Professor 
Affiliation  SDM College of Medical Sciences and Hospital 
Address  Laboratory for Advanced Research in Yoga and Vascular Physiology, Department of Physiology, SDM College of Medical Sciences and Hospital, Manjushree Nagar, Sattur, Dharwad

Dharwad
KARNATAKA
580009
India 
Phone  9986789583  
Fax    
Email  satish.patil@sdmuniversity.edu.in  
 
Source of Monetary or Material Support  
Indian Council of Medical Research. V. Ramalingaswami Bhawan, P.O. Box No. 4911. Ansari Nagar, New Delhi - 110029, India.  
 
Primary Sponsor  
Name  Indian Council of Medical Research (ICMR) 
Address  Indian Council of Medical Research. V. Ramalingaswami Bhawan, P.O. Box No. 4911. Ansari Nagar, New Delhi - 110029, India.  
Type of Sponsor  Government funding agency 
 
Details of Secondary Sponsor  
Name  Address 
VGST KSTEPS  Vijnana Bhavana, 3rd Floor, 21st Main, 24/2, 17th Cross Rd, Banashankari Stage II, Banashankari, Bengaluru, Karnataka 560070 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Vindya Vasu Shetty  SDM College of Medical Science and Hospital  Laboratory for Advanced Research in Yoga and Vascular Physiology, Department of Physiology, SDM College of Medical Sciences and Hospital, Manjushree Nagar, Sattur, Dharwad
Dharwad
KARNATAKA 
9535603717

drvindyashetty@gmail.com 
 
Details of Ethics Committee
Modification(s)  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
IEC-SDMCMSH   Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: I502||Systolic (congestive) heart failure,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Comparator Agent  Enhanced Standard care  The control group will receive enhanced standard care with three educational advice sessions.  
Intervention  Yoga-CaRe programme  Yoga based cardiac rehabilitation(Yoga-CaRe)programme participants will receive 20 supervised sessions spread over a period of three months scheduled twice a week for the first seven weeks and once a week between 8 to 13 weeks. Participants practice at home daily between the supervised sessions 
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  80.00 Year(s)
Gender  Both 
Details  Patients suffering from HF and healthy individuals will be selected for the study. The inclusion criteria for study eligibility for HF patients will be as follows: Male and female patients above 18 years; Physician diagnosed HF based on ESC guidelines, and patients should be NYHA class II/III; HF with reduced ejection fraction ≤ 40%.  
 
ExclusionCriteria 
Details  Comorbid disease or behavioral or other limitations that interfere with performing Yoga training or prevent the completion of 1 y of exercise training; Elective Cardiovascular procedure or hospitalization planned in the coming 3 months; Heart failure secondary to significant correctable/reversible cause like primary valvular disease/ correctable congential heat disease; participation in exercise training/yoga at regular intervals (more than once per week) at a moderate-to-vigorous intensity at any time in the last 6 weeks; and participation in other clinical trials. 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Centralized 
Blinding/Masking   Open Label 
Primary Outcome  
Outcome  TimePoints 
Primary outcomes are change in the flow mediated dilatation (FMD: endothelial dependent) or brachial artery reactivity and functional exercise capacity (6-minute walk test).   3 months 
 
Secondary Outcome
Modification(s)  
Outcome  TimePoints 
1.Secondary outcomes are changes in arterial compliance & stiffness, biomarkers of
endothelial dysfunction, oxidative stress & inflammation
2.Rapid changes in global gene expression profiles in the
peripheral blood mononuclear cells following the immediate practice of
Yoga CaRe for seven days.  
3 months 
 
Target Sample Size
Modification(s)  
Total Sample Size="78"
Sample Size from India="78" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   N/A 
Date of First Enrollment (India)   30/12/2023 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="2"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)
Modification(s)  
Open to Recruitment 
Recruitment Status of Trial (India)  Open to Recruitment 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - YES
  1. What data in particular will be shared?
    Response - All of the individual participant data collected during the trial, after de-identification.

  2. What additional supporting information will be shared?
    Response -  Study Protocol
    Response -  Statistical Analysis Plan
    Response - Informed Consent Form

  3. Who will be able to view these files?
    Response - Anyone

  4. For what types of analyses will this data be available?
    Response - For individual participant data meta-analysis.

  5. By what mechanism will data be made available?
    Response - Proposals should be directed to [drvindyashetty@gmail.com].

  6. For how long will this data be available start date provided 11-12-2025 and end date provided 11-12-2030?
    Response - Immediately following publication. No end date.

  7. Any URL or additional information regarding plan/policy for sharing IPD? 
    Additional Information - NIL
Brief Summary
Modification(s)  

Heart Failure (HF) is a complex clinical syndrome with symptoms and signs that result from any structural or functional impairment of ventricular filling or ejection of blood. HF is a devastating, resource-intensive syndrome that necessitates several pharmacotherapies and causes early mortality, disability, impaired functional capacity, and decreased quality of life. The incidence of HF in India is estimated to be between 0.5 and 1.7 cases per 1000 person per year, for a total of 0.49 million to 1.8 million new cases per year. An effective therapeutic approach for HF still remains a challenging unmet need. Despite the successful control of CV risk factors with several strategies including drugs, the prognosis is poor with current standard therapy with 65% mortality rate at 5 years. Cardiac Rehabilitation is the process of restoring desirable levels of Physical by Physiotherapist (Exercise therapy), Social Counseling by Dietitian (Smoking cessation, Nutritional Counseling, lifestyle modifications), and psychological functioning by Psychologists (Stress reduction sessions, Counseling & medications for depression) after the onset of cardiovascular illness. It is an effective intervention for the prevention of cardiovascular events. Yoga is an ancient Indian mind-body medicine that works in all aspects of a person. All the 3 elements which require 3 different disciplines which covered in Cardiac Rehabilitation are carried out by single Yoga Physician. A meta-analysis showed Yoga as an effective mind-body approach to improve exercise tolerance and Quality of Life in HF patients. An effective therapeutic approach for HF still remains a challenging unmet need. Endothelial dysfunction has been proposed as a potential target for new therapy development and research in HF treatment. In the present context, a comprehensive holistic -approach that improves endothelial function may be an effective therapy for HF. Yoga based intervention has been shown to improve exercise tolerance and pumping function of the heart, but there are gaps in the understanding of the mechanism underlying the improvement in the heart failure with Yoga and its effect on endothelial system remains to be determined. The study will investigate whether Yoga based cardiac rehabilitation program will induce any improvement in endothelial system, arterial function, oxidative stress and inflammation and will look at how it may contribute in beneficial modulation of systolic and diastolic function of heart. The study will also help in identifying the novel target molecules for effective therapy for HF

Applicability: A well-designed RCT of Yoga-CaRe on endothelial system in heart failure is not available. Further, the precise mechanism underlying the effect of Yoga-CaRe on HF remains to be elucidated. The study will investigate whether endothelial function, expression of endothelial genes and its products are influenced by Yoga, and will look at how it may contribute in beneficial modulation of systolic and diastolic function of the heart; and associated co-morbidities as a result of participation in the CR program. Also determine the effect of Yoga-CaRe program on expression of those genes whose products affect vascular and heart health. The study will help in understanding the underlying mechanism of Yoga (through changes in the endothelial function) on HF and in identifying the target molecules for effective therapy for HF

Objectives 


1. To determine if Yoga CaRe may improve endothelial function through enhancement of endothelial-dependent vasodilation after 3 months of Yoga CaRe training. 

2. To assess the rapid changes in global gene expression profiles in the peripheral blood mononuclear cells immediately after Yoga CaRe training in patients with systolic HF

3. To determine the effect of three months of Yoga CaRe on endothelial-related genes, DNA methylation, central blood pressure, arterial stiffness, oxidative stress, and inflammatory markers.

4. To find whether Yoga CaRe-induced changes in vascular function and associated genes are associated with outcomes in HF.  

Method of assessment and data collection: Data will be collected at baseline and post-intervention. The following parameters will be investigated:

  i. Functional exercise capacity: Functional exercise capacity in HF patients will be evaluated using a six-minute walk test (6MWT). 

 ii. Echocardiography: Systolic and diastolic function of the heart will be assessed using echocardiography.

 iii. Assessment of Endothelial system:

a. Flow-mediated dilatation (FMD): This is a gold standard parameter for the assessment of endothelial function. The brachial artery diameter (endothelial-dependent and independent dilatation) will be measured using an endothelial function analysis system.

b. Carotid intima-media thickness: This test measures the thickness of the inner two layers of the carotid artery—the intima and media which reflects atherosclerosis and endothelial dysfunction. 

c. Biomarkers of endothelial function: Endothelin-1 will be evaluated using the ELISA method. Total nitric oxide concentration (NOx) will be determined by the Griess method. 

iv. Gene expression profiling:

a. Real-time qRTPCR will be carried out for examination of expression of genes (eNOS, ET-1, TNF-alpha, NADPH oxidase, MMP, Ang-1, VCAM, ICAM) using blood samples.

v. DNA Methylation analysis

a. DNA methylation analysis will be done using Quantitative analysis based on PCR pyrosequencing.

b. Repetitive element methylation will be estimated by performing DNA methylation analysis of ALU and LINE-1 repeated sequences. Measures of ALU and LINE-1 methylation are commonly used as a surrogate of global methylation.

vi. Assessment of arterial health: Arterial stiffness will be evaluated using ARTSENS® Plus, a validated comprehensive vascular health assessment device.  

a. Carotid-to-femoral pulse wave velocity

b. Arterial compliance  (common carotid artery)

c. Peak luminal distension

d. One-point local pulse wave velocity

vii. Central arterial pressure: Carotid arterial pressure will be determined using ARTSENS®. The following carotid arterial pressure will be recorded:

 a. Carotid systolic pressure 

 b. Carotid diastolic pressure 

 c. Carotid pulse pressure

viii. Oxidative stress & inflammatory markers: Oxidized-LDL, total antioxidant capacity, TNF- alpha and HsC-reactive protein will be estimated by the ELISA method. 

ix. Global gene expression: will be analyzed using Significance Analysis of Microarrays (SAM) method.

 


 
Close